The George Washington University Oncology Update Symposium 2025 reviews developments across seven areas of cancer care: genitourinary, lung, breast, hematologic, neuro-oncology and gastrointestinal malignancies, plus new cancer drugs and therapies. Directed by Robert S. Siegel, MD, the program brings disease-specific updates together with discussion of treatment selection and adverse effects. The original symposium was held June 21, 2025, at The Westin Tysons Corner in Falls Church, Virginia, by the GW School of Medicine and Health Sciences and GW Cancer Center. It is intended for oncology professionals and other clinicians seeking a multidisciplinary review of the evidence presented at that meeting.
Learning Objectives
The first four objectives below reflect the supplied program description; the remaining objectives summarize its agenda.
- Evaluate recent medical advances in the diagnosis and treatment of specific malignant diseases.
- Integrate scientific findings and practical clinical tools into treatment decisions and oncology workflows.
- Assess novel pharmacological agents, targeted treatments, immunotherapies, and emerging therapeutic approaches.
- Identify and implement strategies for recognizing and managing adverse effects and complications associated with cancer treatment.
- Review contemporary treatment considerations across major solid tumors and hematologic malignancies.
- Understand how molecular biomarkers, disease characteristics, and clinical evidence influence individualized therapeutic selection.
- Apply multidisciplinary and patient-centered principles to contemporary cancer management.
Topics
-
Welcome Housekeeping Notes
-
Updates in Genitourinary Cancers
-
Updates in Lung Cancer
-
Updates in Breast Cancer
-
Update on Hematologic Malignancies
-
New Drugs and Therapies for Cancer Treatments
-
Updates on Neuro-Oncology
-
GI Malignancies
-
Course Summary Closing Remarks
Faculty
Course director: Robert S. Siegel, MD, Professor of Medicine and Associate Director for Education and Training, GW Cancer Center.
- Jeanny B. Aragon-Ching, MD, FACP — Genitourinary Oncology
- Richard D. Hall, MD, MS — Thoracic Oncology
- Claudine Isaacs, MD, FRCPC — Breast Oncology
- Imad A. Tabbara, MD — Hematologic Malignancies
- Chaoyuan (Charlie) Kuang, MD, PhD — Emerging Cancer Treatments
- Matthias Holdhoff, MD, PhD — Neuro-Oncology
- David H. Ilson, MD, PhD, FACP, FASCO — Gastrointestinal Oncology
Original Program and Package Scope
The original live activity ran from 8:00 AM to 4:20 PM Eastern Daylight Time and carried up to 7 AMA PRA Category 1 Credits™, 7 ABIM MOC points and 7 completion credits for eligible participants. Those benefits, university registration, accounts, archived platform recordings and publisher-hosted materials are not included with this purchase. A separately sponsored lunch forum is not established as part of the recording package.



